Kyverna Therapeutics, Inc.（KYTX）内部人交易：高管与董事近期交易
过去 18 个月，共有 16 位内部人为 Kyverna Therapeutics, Inc.（KYTX）报告了 25 笔 Form 4 交易（最近一笔 2026-05-29）。
| 日期 | 内部人 | 职务 | 类型 | 股数 | 市值 |
|---|---|---|---|---|---|
| 2026-05-29 | CLARK IAN T | 董事 | 买入 | 5,093 | $0 |
| 2026-05-29 | Cohen Fred E | 董事 | 买入 | 5,093 | $0 |
| 2026-05-29 | Aktar Mert | 董事 | 买入 | 5,093 | $0 |
| 2026-05-29 | Shaw Christi | Executive Chairperson | 卖出 | 4,194 | $36,026 |
| 2026-05-29 | SEIDENBERG BETH C | 董事 | 买入 | 5,093 | $0 |
| 2026-03-17 | Biddle Warner Weston | Chief Executive Officer | 买入 | 58,000 | $0 |
| 2026-03-17 | GRASSO MARC | Chief Financial Officer | 买入 | 10,000 | $0 |
| 2026-03-17 | GEHCHAN NAJI | See Remarks | 买入 | 18,000 | $0 |
| 2026-03-04 | Miller Andrew Craig | 董事 | 买入 | 11,006 | $0 |
| 2026-02-26 | Emany Sravan Kumar | 董事 | 买入 | 11,006 | $0 |
| 2026-01-14 | Shaw Christi | Executive Chairperson | 买入 | 30,000 | $0 |
| 2026-01-14 | Shaw Christi | Executive Chairperson | 买入 | 24,301 | $0 |
| 2025-12-22 | Westlake BioPartners Fund I, L.P. | 10% 以上股东 | 买入 | 133,333 | $999,998 |
| 2025-12-22 | Westlake BioPartners Opportunity GP I, LLC | 10% 以上股东 | 买入 | 133,333 | $999,998 |
| 2025-12-22 | Westlake BioPartners Opportunity Fund I, L.P. | 10% 以上股东 | 买入 | 133,333 | $999,998 |
| 2025-12-22 | Westlake BioPartners GP I, LLC | 10% 以上股东 | 买入 | 133,333 | $999,998 |
| 2025-12-22 | SEIDENBERG BETH C | 董事 | 买入 | 133,333 | $999,998 |
| 2025-12-17 | Walker Karen Marie | Chief Technology Officer | 买入 | 23,998 | $115,910 |
| 2025-12-17 | Walker Karen Marie | Chief Technology Officer | 卖出 | 23,998 | $292,776 |
| 2025-06-02 | Aktar Mert | 董事 | 买入 | 16,634 | $0 |
| 2025-06-02 | SPIEGELMAN DANIEL K | 董事 | 买入 | 16,634 | $0 |
| 2025-06-02 | CLARK IAN T | 董事 | 买入 | 16,634 | $0 |
| 2025-06-02 | SEIDENBERG BETH C | 董事 | 买入 | 16,634 | $0 |
| 2025-06-02 | Shaw Christi | 董事 | 买入 | 16,634 | $0 |
| 2025-06-02 | Cohen Fred E | 董事 | 买入 | 16,634 | $0 |
来源：SEC Form 4 申报文件 · 截至 2026-05-29